NCT02886065 - A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2026

Conditions

Smoldering Multiple Myeloma

Interventions

DRUG

Hiltonol

Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration

DRUG

Citarinostat

Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.

DRUG

Lenalidomide

Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.

BIOLOGICAL

PVX-410

PVX-410 Biweekly (0.8 mg) via subcutaneous injection

Trial Locations (6)

Weill Cornell Medical College, New York

Duke University Medical Center, Durham

University Hospital of Cleveland- Seidman Cancer Center, Cleveland

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston